Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026

Published: 2026-05-07 09:50:37 ET APLS

Published on 05/07/2026 at 09:50 am EDT

Apellis Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 268.3 million compared to USD 166.8 million a year ago. Net income was USD 18.66 million compared to net loss of USD 92.23 million a year ago.

Basic earnings per share from continuing operations was USD 0.15 compared to basic loss per share from continuing operations of USD 0.74 a year ago. Diluted earnings per share from continuing operations was USD 0.15 compared to diluted loss per share from continuing operations of USD 0.74 a year ago.